Floatz logo

Sonidegib

PTCH1 or SMO Activated Solid and Hematologic Tumors

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the PTCH1 or SMO Activated Solid and Hematologic Tumors cohort.

Asset / SponsorPhaseRating
Bortezomib
Novartis Pharmaceuticals
Phase 2CCC

Same molecule, other indications

Sonidegib is also rated in:

acute leukemiaDormant
B
Indicative ·
57 / 100
View asset →
medulloblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →